摘要
目的探究益生菌联合美沙拉嗪及康复新液治疗溃疡性结肠炎的疗效及其对炎性因子的影响。方法选取浙江新安国际医院2021年11月至2022年5月收治的溃疡性结肠炎患者106例为研究对象,采用随机数字表法分为联合组、单独组各53例。单独组采用美沙拉嗪治疗,联合组采用美沙拉嗪联合益生菌、康复新液治疗,两组疗程30 d。比较两组临床疗效,治疗前后炎性因子和Rachmilewitz内镜评分变化,观察两组不良反应发生情况。结果联合组总有效率为98.1%(52/53),高于单独组的79.3%(42/53)(χ^(2)=9.40,P<0.05)。治疗后,两组肿瘤坏死因子α(TNF-α)、白细胞介素8(IL-8)、白细胞介素17(IL-17)均明显下降,白细胞介素10(IL-10)均明显上升(均P<0.05);联合组TNF-α、IL-8、IL-17水平和Rachmilewitz内镜评分明显均低于单独组(t=-2.22、-5.85、-14.08、-2.62,均P<0.05),IL-10水平明显高于单独组(t=3.91,P<0.05)。联合组临床症状发生率为11.3%(6/53),低于单独组的54.7%(29/53)(χ^(2)=22.57,P<0.001)。两组不良反应率差异无统计学意义(P=0.540)。结论采用益生菌联合美沙拉嗪及康复新液治疗溃疡性结肠炎,可提高治疗效果,降低患者炎性因子水平,减轻患者的临床症状,且不良反应较少。
Objective To investigate the efficacy of probiotics,mesalazine and Kangfuxin liquid in combination on ulcerative colitis and its effects on inflammatory factors.Methods A total of 106 patients with ulcerative colitis admitted to Zhejiang Sian International Hospital from November 2021 to May 2022 were included in this study.They were randomly assigned to receive treatment with either probiotics,mesalazine and Kangfuxin liquid in combination(combined therapy group,n=53)or mesalazine alone(monotherapy group,n=53)for 30 days.Clinical efficacy,inflammatory factor level and Rachmilewitz endoscopic score pre-and post-treatment as well as the incidence of adverse reactions were compared between the two groups.Results Total response rate in the combined therapy group was significantly higher than that in the monotherapy group[98.1%(52/53)vs.79.3%(42/53),χ^(2)=9.40,P<0.05].After treatment,tumor necrosis factor-a,interleukin-8,and interleukin-17 levels were significantly decreased,and interleukin-10 level was significantly increased(all P<0.05).Tumor necrosis factor-a,interleukin-8,and interleukin-17 levels as well as Rachmilewitz endoscopic score in the combined therapy group were significantly lower than those in the monotherapy group(t=-2.22,-5.85,-14.08,-2.62,all P<0.05).The interleukin-10 level in the combined therapy group was significantly higher than that in the monotherapy group(t=3.91,P<0.05).The incidence of clinical symptoms in the combined therapy group was significantly lower than that in the monotherapy group[11.3%(6/53)vs.54.7%(29/53),χ^(2)=22.57,P<0.001].There was no significant difference in the incidence of adverse reactions between the two groups(P=0.540).Conclusion Probiotics,mesalazine and Kangfuxin liquid in combination for the treatment of ulcerative colitis can improve clinical efficacy,decrease inflammatory factor levels,reduce clinical symptoms,and have a few adverse reactions.
作者
徐晓
陈涛
尹强龙
张禹
Xu Xiao;Chen Tao;Yin Qianglong;Zhang Yu(Department of Gastroenterology,Zhejiang Sian International Hospital,Jiaxing 314000,Zhejiang Province,China;Department of Gastroenterology,General Hospital of Taiyuan Iron and steel(Group)Co.,Ltd.,Taiyuan 030003,Shanxi Province,China)
出处
《中国基层医药》
CAS
2023年第5期683-687,共5页
Chinese Journal of Primary Medicine and Pharmacy
